Emindole SB
Emindole SB is an anticancer agent. Emindole SB can be isolated from Penicillium species. Emindole SB exerts anticancer effects against ovarian cancer, breast cancer and lymphoma. Emindole SB shows no toxicity to Caenorhabditis elegans. Emindole SB can be used in studies related to ovarian cancer, lymphoma and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 112900-04-6
- Formule: C28H39NO
- Masse moléculaire:405.63
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
Fungal Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
8.2 μM
Compound: 10
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31117519] |
Emindole SB (at increasing concentrations; 72 h) inhibits the viability of mouse lymphoma L5178Y cells, with an IC50 of 18.3 μM[1].
Emindole SB (at increasing concentrations; 72 h) inhibits the viability of ovarian cancer A2780 cells, with an IC50 of 8.2 μM and a selectivity index of 5.4 relative to embryonic kidney HEK-293 cells[1].
Emindole SB (at increasing concentrations; 72 h) inhibits the viability of embryonic kidney HEK-293 cells with an IC50 of 44.6 μM[1].
Emindole SB (increasing concentrations; 72 h) exhibits no cytotoxic activity against bladder urothelial carcinoma cell line J82[1].
Emindole SB (72 h) inhibits the proliferation of breast cancer MCF-7 and MDA-MB-231 cells, with an IC50 of 10.1 μM for the former and 21.3 μM for the latter[2].
Emindole SB (multiple treatments; 24 h) inhibits the migration of breast cancer MDA-MB-231 cells, with an IC50 value of 19.0 μM[2].
Emindole SB (7.5-15.0 μM; 24 h) does not inhibit the invasion of breast cancer MDA-MB-231 cells at concentrations of 7.5 μM or 15.0 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:murine lymphoma L5178Y cells
-
Concentration:increasing concentrations
-
Incubation Time:72 h
-
Result:Exhibited cytotoxic activity against L5178Y cells with an IC50 value of 18.3 μM.
-
Cell Line:human ovarian cancer A2780 cells
-
Concentration:increasing concentrations
-
Incubation Time:72 h
-
Result:Exhibited pronounced cytotoxic activity against A2780 cells with an IC50 value of 8.2 μM.
Demonstrated a selectivity index (SI) of 5.4 calculated as the IC50 against HEK-293 cells divided by the IC50 against A2780 cells.
-
Cell Line:human embryonic kidney HEK-293 cells
-
Concentration:increasing concentrations
-
Incubation Time:72 h
-
Result:Exhibited cytotoxic activity against HEK-293 cells with an IC50 value of 44.6 μM.
-
Cell Line:human breast cancer MCF-7, MDA-MB-231 cell lines
-
Concentration:Multiple doses
-
Incubation Time:72 h
-
Result:Inhibited proliferation of MCF-7 cells with an IC50 of 10.1 μM.
Inhibited proliferation of MDA-MB-231 cells with an IC50 of 21.3 μM.
-
Cell Line:human breast cancer MDA-MB-231 cell line
-
Concentration:Multiple doses
-
Incubation Time:24 h
-
Result:Inhibited migration of MDA-MB-231 cells with an IC50 of 19.0 μM.
Emindole SB (10-50 μM; plate-incorporated; continuous exposure from L1 stage onward) shows no detectable toxicity to Caenorhabditis elegans at exposure concentrations up to 50 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type N2 Bristol strain (synchronized L1 stage larvae, incubated to L4 larval stage)[2]
-
Dosage:1.0 μM
-
Administration:plate-incorporated; continuous exposure from L1 to L4 larval stage
-
Result:Exhibited reversal counts comparable to vehicle (DMSO) control, with no statistically significant increase relative to control.
-
Animal Model:wild-type N2 Bristol strain (synchronized L1 stage larvae, observed over 7 days post-exposure)[2]
-
Dosage:10 μM; 50 μM
-
Administration:plate-incorporated; continuous exposure from L1 stage onward
-
Result:Showed no generalized effects on nematode viability or reproduction at either concentration.
Chemical Information
-
CAS No. 112900-04-6
-
Masse moléculaire 405.63
-
Formule C28H39NO
-
SMILES
C[C@]12C3=C(C[C@@]1(CC[C@@]4([C@]2(C)CC[C@H](O)[C@]4(CCC=C(C)C)C)[H])[H])C=5C(N3)=CC=CC5
-
Structure Classification
-
Initial Source
Aspergillus oryzae
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Ariantari NP, et al. Indole Diterpenoids from an Endophytic Penicillium sp. J Nat Prod. 2019;82(6):1412-1423. [Content Brief]
[2]. Sallam AA, et al. Bioguided discovery and pharmacophore modeling of the mycotoxic indole diterpene alkaloids penitrems as breast cancer proliferation, migration, and invasion inhibitors. Medchemcomm. 2013;4(10):10.1039/C3MD00198A. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Emindole SB Related Classifications
HY-N19113 Related Classifications
Powered by Bioz
- Emindole SB
- 112900-04-6
- Endogenous Metabolite
- BK channel
- human embryonic kidney HEK-293 cells
- murine lymphoma L5178Y cells
- human urothelial bladder cancer J82 cells
- human ovarian cancer A2780 cells
- lymphoma
- breast cancer
- Caenorhabditis elegans
- ovarian cancer
- human breast cancer MCF-7 cells
- Inhibitor
- inhibitor
- inhibit